Flanagan T - Search Results

1

Towards the development of a paediatric biopharmaceutics classification system: Results of a survey of experts.

Batchelor H, Ernest T, Flanagan T, Klein S, Turner R, Fotaki N, Storey D; EuPFI. Batchelor H, et al. Among authors: flanagan t. Int J Pharm. 2016 Sep 25;511(2):1151-7. doi: 10.1016/j.ijpharm.2016.06.115. Epub 2016 Jun 25. Int J Pharm. 2016. PMID: 27349792 Free article. Review.

2

Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations.

Liu F, Ranmal S, Batchelor HK, Orlu-Gul M, Ernest TB, Thomas IW, Flanagan T, Tuleu C. Liu F, et al. Among authors: flanagan t. Drugs. 2014 Oct;74(16):1871-1889. doi: 10.1007/s40265-014-0297-2. Drugs. 2014. PMID: 25274536 Free PMC article. Review.

3

Formulation factors affecting acceptability of oral medicines in children.

Liu F, Ranmal S, Batchelor HK, Orlu-Gul M, Ernest TB, Thomas IW, Flanagan T, Kendall R, Tuleu C; European Paediatric Formulation Initiatives EuPFI. Liu F, et al. Among authors: flanagan t. Int J Pharm. 2015 Aug 15;492(1-2):341-3. doi: 10.1016/j.ijpharm.2015.05.013. Epub 2015 May 7. Int J Pharm. 2015. PMID: 25959115 Free article.

4

Use of physiologically relevant biopharmaceutics tools within the pharmaceutical industry and in regulatory sciences: Where are we now and what are the gaps?

Flanagan T, Van Peer A, Lindahl A. Flanagan T, et al. Eur J Pharm Sci. 2016 Aug 25;91:84-90. doi: 10.1016/j.ejps.2016.06.006. Epub 2016 Jun 7. Eur J Pharm Sci. 2016. PMID: 27283487

5

Martir J, Flanagan T, Mann J, Fotaki N. Martir J, et al. Among authors: flanagan t. J Pharm Pharmacol. 2017 Apr;69(4):384-397. doi: 10.1111/jphp.12635. Epub 2016 Oct 5. J Pharm Pharmacol. 2017. PMID: 27704550 Review.

6

Biopharmaceutical aspects and implications of excipient variability in drug product performance.

Zarmpi P, Flanagan T, Meehan E, Mann J, Fotaki N. Zarmpi P, et al. Among authors: flanagan t. Eur J Pharm Biopharm. 2017 Feb;111:1-15. doi: 10.1016/j.ejpb.2016.11.004. Epub 2016 Nov 11. Eur J Pharm Biopharm. 2017. PMID: 27845182 Free article. Review.

7

In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context.

Lennernäs H, Lindahl A, Van Peer A, Ollier C, Flanagan T, Lionberger R, Nordmark A, Yamashita S, Yu L, Amidon GL, Fischer V, Sjögren E, Zane P, McAllister M, Abrahamsson B. Lennernäs H, et al. Among authors: flanagan t. Mol Pharm. 2017 Apr 3;14(4):1307-1314. doi: 10.1021/acs.molpharmaceut.6b00824. Epub 2017 Mar 1. Mol Pharm. 2017. PMID: 28195732

8

Potential for pharmaceutical excipients to impact absorption: A mechanistic review for BCS Class 1 and 3 drugs.

Flanagan T. Flanagan T. Eur J Pharm Biopharm. 2019 Aug;141:130-138. doi: 10.1016/j.ejpb.2019.05.020. Epub 2019 May 22. Eur J Pharm Biopharm. 2019. PMID: 31128247 Review.

9

Surface dissolution UV imaging for characterization of superdisintegrants and their impact on drug dissolution.

Zarmpi P, Flanagan T, Meehan E, Mann J, Fotaki N. Zarmpi P, et al. Among authors: flanagan t. Int J Pharm. 2020 Mar 15;577:119080. doi: 10.1016/j.ijpharm.2020.119080. Epub 2020 Jan 24. Int J Pharm. 2020. PMID: 31988030

10

Biopharmaceutical Understanding of Excipient Variability on Drug Apparent Solubility Based on Drug Physicochemical Properties. Case Study: Superdisintegrants.

Zarmpi P, Flanagan T, Meehan E, Mann J, Fotaki N. Zarmpi P, et al. Among authors: flanagan t. AAPS J. 2020 Feb 11;22(2):46. doi: 10.1208/s12248-019-0406-y. AAPS J. 2020. PMID: 32048079 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

349 results

Search Page

Filters